Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 4/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.56 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 6/20 | 0.53 |
| ▸ | NPC1 | O15118 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 5/20 | 0.52 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.52 |
| ▸ | STAT3 | P40763 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14742578 | 0.88 | CYP1A2 (0.56) | EGFRLMNAMAPK1CYP1A2CYP2C19 | |
| SCHEMBL2657168 | 0.86 | CYP1A2 (0.54) | EGFRLMNAMAPK1ANO1CYP1A2 | |
| SCHEMBL5041112 | 0.83 | EGFR (0.73) | EGFRLMNAMAPK1ANO1CYP1A2 | |
| SCHEMBL525280 | 0.81 | MEN1 (0.56) | LMNAMAPK1RAB9ANPC1MEN1 | |
| SCHEMBL525057 | 0.81 | RAB9A (0.60) | LMNAMAPK1CYP1A2CYP2C19RAB9A | |
| SCHEMBL31661283 | 0.80 | MEN1 (0.67) | LMNAMAPK1RAB9ANPC1MEN1 | |
| SCHEMBL525917 | 0.79 | RAB9A (0.50) | LMNAMAPK1RAB9ANPC1MEN1 | |
| SCHEMBL13879960 | 0.78 | CYP1A2 (0.69) | EGFRLMNAMAPK1ANO1CYP1A2 | |
| SCHEMBL4722539 | 0.78 | L3MBTL1 (0.58) | EGFRLMNAMAPK1ANO1CYP1A2 | |
| SCHEMBL5213498 | 0.77 | CYP1A2 (0.57) | EGFRLMNAMAPK1ANO1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513430-B2 | Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta HSD1 modulators | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-08-20 | — | — | US | disclosed |
| US-20120029029-A1 | SUBSTITUTED THIAZOL-2-YLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS 11-BETA HSD1 MODULATORS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-02-02 | — | — | US | disclosed |
| WO-2012015715-A1 | SUBSTITUTED THIAZOL-2-YLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS 11-BETA HSD1 MODULATORS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029029-A1 | SUBSTITUTED THIAZOL-2-YLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS 11-BETA HSD1 MODULATORS | HSD11B1, HSD11B2, HSD3B1 | EGFR 4802/4885LMNA 2567/4885MAPK1 923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.